Introducing a New Concept for Value-Driven Acceleration in Biopharma Development

This opinion paper seeks to introduce a disruptive model to accelerate product and process development in the biopharmaceutical industry, especially for vaccines. This model is based on the minimum valuable product and process (MVaP&P), a new concept that allows for adaptation and acceleration, which would enable agility in the way biopharmaceuticals are developed. This article discusses how the MVaP&P approach would make it is possible to discipline and structure biopharmaceutical development to achieve a phase-appropriate and strategy-aligned product in the fastest time possible.

Peer-reviewed research

Submitted: May 12, 2022
Article accepted: June 28, 2022

About the authors

Matthew Sanders* is vice-president, head of Global Drug Substance; Roland Mainil is director, Technical Development Lead; and Wael Chahim* is associate director, Development Unit Head; all at GSK, Rixensart, Belgium.

*Both authors contributed equally to this paper.

Article details

BioPharm International
Vol. 35, No. 10
October 2022
Pages: 34–41

Citation

When referring to this article, please cite it as M. Sanders, R. Mainil, and W. Chahim, “Introducing a New Concept for Value-Driven Acceleration in Biopharma Development,” BioPharm International 35 (10) 34–41 (2022).